

# Davine Hofste op Bruinink

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3015857/publications.pdf>

Version: 2024-02-01

15  
papers

250  
citations

1163117

8  
h-index

1199594

12  
g-index

15  
all docs

15  
docs citations

15  
times ranked

392  
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission â€œ results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. BMC Cancer, 2022, 22, 147.	2.6	1
2	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. Journal of Clinical Oncology, 2022, 40, 3132-3150.	1.6	13
3	Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia, 2022, 36, 1887-1897.	7.2	23
4	The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nature Immunology, 2021, 22, 769-780.	14.5	107
5	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. Blood Cancer Journal, 2021, 11, 106.	6.2	31
6	Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network. Haematologica, 2021, 106, 1496-1499.	3.5	9
7	Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. American Journal of Hematology, 2019, 94, 1364-1373.	4.1	22
8	IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. Endocrine, 2019, 64, 673-684.	2.3	23
9	Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial. Blood, 2018, 132, 3186-3186.	1.4	3
10	Whole-Exome and mRNA Sequencing of Multiple Myeloma Reveal Transformation to a More High-Risk and Proliferative Tumor at Relapse. Blood, 2018, 132, 3157-3157.	1.4	0
11	Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.. Journal of Clinical Oncology, 2017, 35, 8011-8011.	1.6	15
12	Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity. Blood, 2016, 128, 2072-2072.	1.4	1
13	Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis. Blood, 2016, 128, 3271-3271.	1.4	2
14	Targeted Genomic Mutation Panel (M3 P) Results from 504 Multiple Myeloma (MM) Patients. Blood, 2015, 126, 1795-1795.	1.4	0
15	M3P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma. Blood, 2015, 126, 2984-2984.	1.4	0